Publication: Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexate
Issued Date
2011-01-01
Resource Type
ISSN
1179559X
1179559X
1179559X
Other identifier(s)
2-s2.0-79957788903
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Medicine Insights: Therapeutics. Vol.3, (2011), 125-135
Suggested Citation
Thanyanan Reungwetwattana, Sylvia Jaramillo, Julian R. Molina Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexate. Clinical Medicine Insights: Therapeutics. Vol.3, (2011), 125-135. doi:10.4137/CMT.S3778 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12830
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexate
Other Contributor(s)
Abstract
Peripheral T-cell lymphomas (PTCL) represent about 12%-15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL. © the author(s), publisher and licensee Libertas Academica Ltd.